Literature DB >> 12086877

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.

Masahiro Inoue1, Jeffrey H Hager, Napoleone Ferrara, Hans-Peter Gerber, Douglas Hanahan.   

Abstract

In the RIP1-Tag2 mouse model of pancreatic islet carcinoma, angiogenesis is switched on in a discrete premalignant stage of tumor development, persisting thereafter. Signaling through VEGF receptor tyrosine kinases is a well-established component of angiogenic regulation. We show that five VEGF ligand genes are expressed in normal islets and throughout islet tumorigenesis. To begin dissecting their contributions, we produced an islet beta cell specific knockout of VEGF-A, resulting in islets with reduced vascularity but largely normal physiology. In RIP1-Tag2 mice wherein most oncogene-expressing cells had deleted the VEGF-A gene, both angiogenic switching and tumor growth were severely disrupted, as was the neovasculature. Thus, VEGF-A is crucial for angiogenesis in a prototypical model of carcinogenesis, whose loss is not readily compensated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086877     DOI: 10.1016/s1535-6108(02)00031-4

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  111 in total

Review 1.  Sunitinib in pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Pascal Hammel; Chantal Dreyer; Christian Maatescu; Olivia Hentic; Philippe Ruszniewski; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-06-02       Impact factor: 4.493

2.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

3.  Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.

Authors:  Benelita Tina Elie; Vasilena Gocheva; Tanaya Shree; Stacie A Dalrymple; Leslie J Holsinger; Johanna A Joyce
Journal:  Biochimie       Date:  2010-05-04       Impact factor: 4.079

4.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

Authors:  Barbara Sennino; Beverly L Falcón; Dilara McCauley; Tom Le; Thomas McCauley; Jeffrey C Kurz; Amy Haskell; David M Epstein; Donald M McDonald
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

5.  ERKs activation and calcium signaling are both required for VEGF induction by vanadium in mouse epidermal Cl41 cells.

Authors:  Jingxia Li; Qiangsong Tong; Xianglin Shi; Max Costa; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

6.  Perinatal development of the pancreatic islet microvasculature in rats.

Authors:  Magnus Johansson; Arne Andersson; Per-Ola Carlsson; Leif Jansson
Journal:  J Anat       Date:  2006-02       Impact factor: 2.610

7.  Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling.

Authors:  Jun Qin; Xinpu Chen; Li-Yuan Yu-Lee; Ming-Jer Tsai; Sophia Y Tsai
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

Review 8.  Islet vasculature as a regulator of endocrine pancreas function.

Authors:  Nikiforos Ballian; F Charles Brunicardi
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 9.  Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours.

Authors:  E Raymond; S Faivre
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

Review 10.  New advances in targeted gastric cancer treatment.

Authors:  Daniela Cornelia Lazăr; Sorina Tăban; Marioara Cornianu; Alexandra Faur; Adrian Goldiş
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.